<DOC>
	<DOCNO>NCT01011244</DOCNO>
	<brief_summary>Up date , sure cure Crohn 's fistula know fistula recurrence rate high . On 15 October 2008 , orphan designation grant Korea FDA human adipose-derived stem cell ( ADIPOPLUS ) treatment Crohn 's fistula . In study , patient give injection ADIPOPLUS fistula site follow 8 week evaluate safety efficacy .</brief_summary>
	<brief_title>Safety Efficacy Study Autologous Cultured Adipose -Derived Stem Cells Crohn 's Fistula</brief_title>
	<detailed_description />
	<mesh_term>Fistula</mesh_term>
	<criteria>Older 18 year Prior diagnosis Crohn 's disease patient Crohn 's fistula negative serum betaHCG woman childbearing age agreement participate , sign informedconsent patient allergy bovinederived material anesthetic patient diagnosis auto immune disease except Crohn 's disease Diagnosis HBV , HCV , HIV infectious disease Patients symptom septicemia Patients diagnosis active Tuberculosis Patient pregnant breastfeeding Patients unwilling use `` effective '' method contraception study Patients diagnosis Inflammatory Bowel Disease except Crohn 's disease Patients sensitive Fibrin glue Patients clinically relevant history abuse alcohol drug , habitual smoker Insufficient adipose tissue manufacture ADIPOPLUS Patients consider suitable study investigator Patients diagnosis active refractory Crohn 's disease Patients history surgery malignant cancer past 5 year Patients &gt; 2 cm diameter fistula</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>